Estrella Immunopharma, Inc. (ESLA): Net Income

Annual figures by period end, from SEC filings.

-$13.06M

Year ended 2025-12-31

-$10.01M

Trailing 12 months to 2026-06-30

2021-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$13.06M	n/a	2026-03-18, From 2025-01-01
No annual figure between 2024-06-30 and 2025-12-31.
2024-06-30	-$7.31M	n/m	2024-09-27, From 2023-07-01
2023-06-30	-$11.11M	n/a	2024-09-27, From 2022-07-01
No annual figure between 2021-12-31 and 2023-06-30.
2021-12-31	-$247.7K	n/a	2023-03-14, From 2021-01-06

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Estrella Immunopharma, Inc. (ESLA)	2025-12-31	-$13.06M	n/a
BioCardia, Inc. (BCDA)	2025-12-31	-$8.23M	n/m
Cero Therapeutics Holdings, Inc. (CERO)	2025-12-31	-$19.92M	n/a
Tevogen Inc. (TVGN)	2025-12-31	-$26.28M	n/m
Eloxx Pharmaceuticals, Inc. (ELOX)	2025-12-31	-$6.00M	n/m
AIM ImmunoTech Inc. (AIM)	2025-12-31	-$13.96M	n/m
Exozymes Inc. (EXOZ)	2025-12-31	-$9.16M	n/m
Zivo Bioscience, Inc. (ZIVO)	2024-12-31	-$13.38M	n/m
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	-$5.52M	n/m

Compare ESLA, BCDA, CERO, TVGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗